WEE1 and central nervous system cancer: In this study, HTS was used to identify drug sensitivities to 357 compounds in the published Protein Kinase Inhibitor Set (PKIS) from GlaxoSmithKline (GSK) using a panel of GSCs, which are representative of the classic cancer genome atlas (TCGA) molecular subtypes [8] and are highly characteristic of human glioma growth patterns that contribute to tumor initiation and therapeutic resistance.